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Objective: Debridement to remove necrotic and/or infected tissue and promote
active healing remains a cornerstone of contemporary chronic wound man-
agement. While there has been a recent shift toward less invasive polymer-
based debriding devices, their efficacy requires rigorous evaluation.
Approach: This study was designed to directly compare monofilament deb-
riding devices to traditional gauze using a wounded porcine skin biofilm model
with standardized application parameters. Biofilm removal was determined
using a surface viability assay, bacterial counts, histological assessment, and
scanning electron microscopy (SEM).
Results: Quantitative analysis revealed that monofilament debriding devices
outperformed the standard gauze, resulting in up to 100-fold greater reduction
in bacterial counts. Interestingly, histological and morphological analyses
suggested that debridement not only removed bacteria, but also differentially
disrupted the bacterially-derived extracellular polymeric substance. Finally,
SEM of post-debridement monofilaments showed structural changes in at-
tached bacteria, implying a negative impact on viability.
Innovation: This is the first study to combine controlled and defined debride-
ment application with a biologically relevant ex vivo biofilm model to directly
compare monofilament debriding devices.
Conclusion: These data support the use of monofilament debriding devices for
the removal of established wound biofilms and suggest variable efficacy to-
wards biofilms composed of different species of bacteria.
Keywords: wound biofilm, debridement, Pseudomonas aeruginosa, Staphylo-
coccus aureus
INTRODUCTION
Nonhealing chronic wounds re-
main a major area of unmet clinical
need, leading to increased patient
morbidity and mortality, while im-
posing a significant financial burden
on healthcare providers worldwide.1,2
Wound chronicity can arise through
malfunction at any stage of repair
and can be influenced by local (e.g.,
ischemia) and systemic factors (e.g.,
age, malnutrition, and disease),
along with imbalances in cytokine
levels and growth factors.1 One of the
most discussed extrinsic causes of
chronicity is the presence of infection,
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where opportunistic ‘‘critical’’ colonization of a
wound bymicroorganisms can lead to the formation
of a biofilm.3–5 Biofilms are becoming increasingly
implicated in pathological healing due to their resis-
tance to the host immune defence and transient
responses to most therapeutic treatments.5,6 Estab-
lished biofilms have a number of distinguishing
characteristics that contribute to their resistant
phenotype, most notably physiological and physio-
chemical effects resulting from encapsulation in a
tough protective layer of extracellular polymeric
substances (EPS).7
While current wound management involves a
multidisciplinary team approach, debridement to
remove necrotic, devitalized, and infected tissue re-
mains a primary consideration in wound manage-
ment.8 Historically, debridement has been suggested
to promote healing by removing nonviable ischemic
tissue and exposing underlying vascularized tissue,
triggering endogenous reparative processes.9 More
recently, it has been suggested that debridement
may also promote healing through the physical dis-
ruption and removal of established wound biofilms.7
CLINICAL PROBLEM ADDRESSED
Traditional debridement techniques, including
sharp excision and curettage can be invasive and
painful, requiring professional administration.10 A
number of alternative, less costly debridement mo-
dalities have beendeveloped over recent years, such
as autolytic and mechanical debridement. Classical
mechanical debridement involves the removal of
necrotic tissue by scrubbing and stripping with
cotton gauze.11 However, scrubbing and stripping
can be invasive, painful, and may scrub the wound
of valuable repair cells, depending on wound eti-
ology and nature.12 Notably, the efficacy of simple
cotton gauze at removing wound biofilms remains
largely untested.13 Recently, new, mechanical,
polymer fiber debriding devices have emerged, de-
signed to remove both established wound biofilms
and devitalized tissue with minimal discomfort
(e.g., Debrisoft; Activa Healthcare, Debrimitt;
Crawford Healthcare Ltd.14).
In this study, we report a detailed side-by-side
comparison to test the efficacy of monofilament
debriding devices versus traditional gauze mate-
rial in mechanical debridement of established ex
vivo porcine wound biofilms.
MATERIALS AND METHODS
Growth of biofilms
Single-colony inoculates of Pseudomonas aeru-
ginosa (NCTC10781) and Staphylococcus aureus
(NCTC13277) were grown overnight in Mueller
Hinton (MH; Oxoid) broth, at 37C with 220 rpm
shaking (Innova 44; NewBrunswick Scientific). The
(O/N) cultures were diluted to obtain densities at c.
107 colony forming units per milliliter (CFU/mL),
verified by spread plating and colony counts. Sterile
filter membranes (0.45lm thick; Merck Millipore
Ltd.) were inoculated with 10lL of diluted cultures
and incubated onMHagar plates for 48h at 37C (as
in Merritt et al.15). The resultant 48h established
biofilms were added to wounded porcine skin.
Porcine skin preparation
Porcine skin was collected of schedule 1 killed fe-
male pigs (weighing 43–45kg) from the abattoir, epi-
lated using dry razors and stored at -80C until use.
Defrosted skinwas cut into1.3·1.3cm2andwounded
by completely removing the epidermis (No. 22 blades;
Swann Norton). The skin squares were sequentially
washed in sterile phosphate buffered saline contain-
ing 5 ug/L TWEEN 20 (PBST), 0.6% sodium hypo-
chlorite (in PBST), and 70% ethanol (in PBST).
Finally, tissuewaswashedthrice insterilephosphate-
buffered saline (PBS) to remove solvent residues
(modified from Yang et al.16). To maintain a humid
environment for bacterial growth, skin squares were
placed in six-well plates on sterile PBS-soaked ab-
sorbent pads. A 48-h established biofilmwas added to
the wounded surface of each porcine biopsy, ensuring
even coverage. Nonbiofilm controls were prepared in
parallel. Biopsies were incubated at 37C for an ad-
ditional 24h to allow further biofilm maturation and
attachment to the wounded porcine skin.
Mechanical debridement and sample
collection
Debriding devices (gauze, Debrisoft, and Deb-
rimitt) were cut into strips, firmly stapled to
toothbrush heads, and loaded into an SD Mecha-
tronik ZM-3 tooth brushing simulator (Fig. 1A).
The porcine biofilm biopsies were glued onto cus-
tom fabricated clay moulds and mounted in the
toothbrush simulator. Each sample was brushed in
a linear manner for 50 cycles at 22mm per second,
with a travel length of 10mm and a constant force
of 12.6 kPa (Fig. 1B). Separate samples were col-
lected for PrestoBlue cell viability analysis (n =3),
bacterial viability counts (n =3), and scanning
electron microscope (SEM) preparation (n = 2) and
embedded in optimum cutting temperature (OCT)
solution for histological analysis (n = 2). In addi-
tion, S. aureus and P. aeruginosa 48-h membrane
biofilms (before addition to porcine skin) were also
collected to confirm the presence of established
biofilms (data not shown).
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PrestoBlue in situ bacterial viability assay
Following debridement, the PrestoBlue Cell
Viability Reagent (Invitrogen, Life Technologies)
was applied evenly to the full surface of each tissue
square and incubated for 3min. Images were cap-
tured (Nikon D3200 Digital SLR camera with a
Nikon AF-S DX Micro NIKKOR 40mm f/2.8G
Lens) and percentage cell viability calculated using
ImagePro-Plus software (Media Cybernetics, Inc.,
Rockville, MD, USA).
Bacterial viability counts
Each sample was cut into small (<1mm) pieces
using an aseptic technique and sterile scalpel blades
(No. 22 blades; Swann Norton), then vortexed in
1mL MH broth with 5mL sterile glass beads (Bor-
osilicate, 3mm diameter; Sigma-Aldrich) for 30 s.
The resultant resuspended bacteria were serial di-
luted and plated in triplicate to determine viable
CFUs per biofilm.
Scanning electron microscopy
Tissue samples (*2mm diameter), cut into tra-
pezium shapes to identify orientation, were fixed
for 4 h in 2% glutaraldehyde/paraformaldehyde in
HEPES buffer, followed by transfer through an
ETOH gradient (10%, 25%, 50%, 70%, 90%, and
3 ·100% for 15min each). Critical point drying was
performed using an E3000 (Quorum Technologies)
in 100% ETOH. Samples underwent three ex-
changes of ETOH for liquid CO2 before heating and
critical point drying. Samples were mounted onto
stubs, placed in an argon vacuum, and sputter
coated (SC7690; Quorum Technologies) with gold
(Quanta Feg 250; FEI Company). Images were ta-
ken at three points per sample at a range of mag-
nifications using a high-vacuum SEM. Gauze,
Debrisoft, and Debrimitt were also collected
post-treatment, processed and dried for SEM as
above, and imaged using low-vacuum SEM.
Histological analysis of frozen tissue sections
OCT embedded samples were cryosectioned
at 12lm (CM3050 S; Leica Biosystems) and stored at
-80C until use. Before staining, sectioned slides at
-80C were brought to -20C and fixed with cold ac-
etone for 2min, which was then left to evaporate at
roomtemperature (<20min).Slideswere immersed in
PBS to remove any residual OCT. Modified Gram–
Twort staining was achieved following Bancroft
and Gamble,17 DPX mounted and imaged using an
Eclipse E600 microscope (Nikon) and SPOT camera
(Image Solutions, Inc.). Biofilm thickness was quan-
tified from Gram–Twort images using ImageJ soft-
ware (NIH). Concanavalin A (ConA) staining for EPS
(Alexa Fluor 488 conjugate, Molecular Probes;
Thermo Fisher Scientific) was performed O/N at 4C.
Sections were mounted in VECTASHIELD with
4¢,6-diamidino-2-phenylindole (DAPI; Vector Labora-
tories Ltd.) to counterstain bacterial DNA. Similarly,
sections were stained with Acridine Orange (Sigma-
Aldrich) to visualize bacteria on host tissue. Fluor-
escent in situhybridization (FISH),usingPNAFISH
kits (AdvanDx, Inc.)withP. aeruginosaandS. aureus
probes, was used to show species specificity. Sections
were imaged on an Olympus Snapshot fluorescence
microscope using fluorescein isothiocyanate, DAPI,
and TEXAS RED filters. S. aureus and P. aeruginosa
membrane biofilms were embedded in OCT, sec-
tioned, and then stained as above.
Statistical analyses
Statistical testswereperformedonallS.aureusand
P. aeruginosa quantitative data (PrestoBlue cell vi-
ability, viability counts, and biofilm thickness), where
treatment (uninoculated skin, established ‘‘control’’
biofilms, gauze dressing, Debrisoft, and Debrimitt)
was plotted against viability/abundance/thickness.
For viability counts and PrestoBlue viability data,
one-way analysis of variances (ANOVAs) were per-
formed in R v3.2.2 (R Development Core Team) with
accompanying Tukey post hoc analyses. Nonpaired
T tests were performed for biofilm thickness data.
RESULTS
Comparative quantification of biofilm
removal postdebridement
Biofilms of P. aeruginosa and S. aureus estab-
lished on wounded porcine skin were subjected to
controlled mechanical debridement with defined
speed, duration, and pressure (Fig. 1). The biofilm
Figure 1. Debriding apparatus. Samples were debrided using an SD
Mechatronik ZM-3 toothbrush simulator (Germany). Diagram of the deb-
riding experiment setup. Debriding devices (gauze, Debrisoft, or Debri-
mitt) were attached to solid supports and inserted into the simulator.
Porcine skin biofilms were attached to custom fabricated clay moulds
positioned directly beneath the debriding devices. A weight of 219 g was
placed at the center of each brush, exerting a force of 12.6 kPa per sample.
Debridement consisted of 50 linear strokes at a speed of 22mm/s.
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remaining postdebridement was assessed by the
following methods:
Surface area coverage of viable biofilm.
PrestoBlue was used to directly visualize the
surface area of porcine skin with the remaining
viable biofilm versus untreated established bio-
films (Fig. 2A; ANOVA: F3,11 =8, p =0.004). In this
study, Debrimitt and Debrisoft significantly re-
duced viableP. aeruginosa biofilm surface coverage
compared to control biofilms that underwent no
debridement (Debrimitt, 95% confidence interval
[CI 23.15–108.13], p =0.003; Debrisoft, 95% CI
[12.45–97.43, p =0.01). Of note, no significant dif-
ference was found between the gauze dressing and
control P. aeruginosa biofilms (95% CI [-2.49–
82.49], p =0.067). A similar trend of surface area
debridement efficacy was observed with S. aureus
biofilms, although the data failed to reach signifi-
cance (ANOVA: F3,8= 3.16, p =0.086).
Quantification of biofilm bacteria. Resuspending
biofilm bacteria to gain quantitative viability data
(Fig. 2B) revealed significantly reduced viable
P. aeruginosa following debridement (ANOVA:
F3,20=67.43, p<0.001). Debrimitt treatment ap-
pearedmost effective, resulting in a 6 log10 reduction
(p<0.001) versus control biofilms. Debrisoft and
gauze debridement both led to 5 log10 reductions in
viable P. aeruginosa (p<0.001 and p<0.001, respec-
tively). S. aureus viability was also significantly re-
duced following debridement (Fig. 2B; ANOVA:
F3,11=81.91, p<0.001). In this study, both Debri-
mitt and Debrisoft treatment led to a 7 log10 re-
duction in S. aureus compared to control biofilms
(p<0.001). By contrast, treatment with a gauze
dressing gave only a 5 log10 reduction in S. aureus
(p<0.001). Overall, the data suggest that all three
debridement modalities remove viable biofilms of S.
aureus andP. aeruginosa fromporcinewound tissue,
with Debrimitt proving most effective.
Visualizing established biofilms in situ
Gram–Twort stain. Frozen histological sections
subjected to Gram–Twort staining confirmed both
the presence and identity (i.e., gram positive vs.
gram negative) of P. aeruginosa (pink stain) and S.
aureus (purple stain) biofilms on the porcinewound
surface (Fig. 3). Control biofilms of gram-negative
P. aeruginosa appeared as a pink continuous mass
Figure 2. Assessment of debridement efficacy. (A) Quantification of biofilm coverage using a resazurin-based cell viability stain. In each case, debridement
reduced biofilm coverage which achieved statistical significance for Debrisoft and Debrimitt application to P. aeruginosa biofilms. (B) Viable counting of bacteria
remaining indicates statistically significant reductions in colony forming units following each treatment. Monofilament debridement outperformed traditional gauze.
Graphs show means; error bars represent SEM. *p< 0.05; **p< 0.01; ***p< 0.001.
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in the wounded porcine skin, mirroring the stain-
ing found in the P. aeruginosa membrane biofilms
(data not shown). Following debridement, the
amount (thickness) of visible bacteria decreased,
with greatest reduction in visible biofilm in the
Debrimitt-treated group (T9 = 2.28, p < 0.05;
Fig. 3C). Note, stainingwas absent from nonbiofilm,
untreated porcine skin. S. aureus, a gram-positive
bacterium stained purple with the Gram–Twort
stain, was readily apparent on the surface of each
control porcine wound biofilm and mimicked the
staining of S. aureus membrane biofilms (data
not shown). Thick aggregated clumps of S. aureus
were readily visualized in nondebrided established
biofilm tissue. These clumps of bacteriawere greatly
diminished following debridement, with the great-
est reduction in biofilm thickness following mono-
filament debridement (Debrisoft and Debrimitt,
p<0.01; Fig. 3D).
ConA, Acridine Orange, and FISH staining.
Next biofilms were stained with a combination of
ConA and DAPI counterstain (Fig. 4). Labeled lec-
tins, such as fluor-conjugated ConA, which interacts
with carbohydrates, are oftenused to indicate biofilm
formation.18 However, EPS staining can vary due to
biofilm-specific variation in polymeric substances.19
The bacteria within the biofilm mass could be visu-
alized by DAPI (blue) (Fig. 4A, D), Acridine Orange
(Fig. 4B, E), and FISH staining (Fig. 4C, F). Control
P. aeruginosa and S. aureus biofilms were both pro-
minent across the surface of the porcine wound. In
Figure 3. High-power modified Gram–Twort stained images confirm the extent of biofilm removal. (A) P. aeruginosa biofilm (red) was evident at the wounded
surface in all but the untreated skin. All three debriding treatments reduced biofilm, with the most efficient removal following Debrimitt treatment. (B) S.
aureus biofilm (purple) was also clearly attached to the surface of the wounded porcine skin. Again, debridement treatment substantially reduced the surface
biofilm. Note, bacteria were observed not just at the surface but also integrated into the host tissue. (C) P. aeruginosa biofilm thickness was significantly
reduced with Debrimitt debridement. (D) S. aureus biofilm thickness was significantly reduced with monofilament debridement. Date shows mean – standard
error of the mean. *p < 0.05; **p< 0.01. Bar (A) = 14.4lm.
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Figure 4. ConA, Acridine Orange, and FISH stained images confirm the extent of biofilm removal. (A) P. aeruginosa biofilms stain for bacterial EPS (green;
ConA) with prominent DAPI (blue) bacteria visible at the porcine wound surface. (B) Acridine Orange staining for bacteria (red/orange) at the surface layers of
the porcine wounds, with green host tissue. (C) FISH of P. aeruginosa (red) from the treatments, including a positive (+ve) slide containing P. aeruginosa (red),
Escherichia coli (green), and Klebsiella pneumoniae (yellow). Debridement reduces apparent biofilm mass with Debrisoft and Debrimitt showing the most
effective removal. (D) S. aureus biofilms exhibit DAPI stained bacterial mass (blue). (E) Acridine Orange staining for bacteria (red/orange) at the wound
surface. (F) FISH of S. aureus (green) from the treatments, including a positive (+ve) slide containing S. aureus (green). S. aureus bacteria are prominent in
nondebrided control samples, which substantially reduced following debridement, particularly following monofilament debridement treatments (Debrisoft and
Debrimitt). Bar (A) = 12.7lm. ConA, concanavalin A; DAPI, 4¢,6-diamidino-2-phenylindole; EPS, extracellular polymeric substances; FISH, fluorescent in situ
hybridization.
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keeping with the Gram–Twort staining, less biofilm
was observed following each debridement treatment,
with greatest reduction in the Debrimitt treatment
group. Note, no biofilm mass (blue DAPI staining,
orange/red Acridine Orange staining, or FISH
staining) was observed in any of the uninoculated
porcine skin samples (Fig. 4).
Scanning electron microscopy. Finally, samples
were subjected to SEM to directly visualize bacteria/
tissue interaction. Control P. aeruginosa biofilm-
treated skin (Fig. 5D) was covered with abundant
rod-shaped P. aeruginosa (pseudocolored pink;
Fig. 5A), encased in a stringy dehydrated EPS
(pseudocolored blue; Fig. 5B), indicative of biofilm
formation. As expected, uninoculated porcinewound
samples lacked a visible bacterial biofilm (Fig. 5C).
Interestingly, the surface of gauze debrided samples
retained virtually full coverage of bacteria, but ex-
hibited less EPS. A substantial proportion of the
bacteria and EPS were removed by both Debrisoft
and Debrimitt treatments, with remaining bacte-
ria mainly residing within the porcine wound tissue
(Fig. 5F, G). SEM imaging of the gauze, Debrisoft,
and Debrimitt following application revealed bac-
terial removal in large clumps, which remain on the
fibers of the devices (Fig. 5H, J). Moreover, at high
resolution, the P. aeruginosa bacteria retained on
the Debrisoft and Debrimitt fibers appeared de-
formed and compressed compared to the P. aerugi-
nosa removed by the gauze (Fig. 5J, inset). This
suggests that debridement using Debrisoft or
Debrimitt may adversely affect bacterial viability.
Similarly, S. aureus (pseudocolored purple,
Fig. 6A) formed an extensive covering on the surface
of control biofilm-treated porcine wounds (Fig. 6D),
Figure 5. SEM images confirm P. aeruginosa biofilm removal following debridement. (A) Pseudocolored rod-shaped P. aeruginosa ( pink). (B) Pseudocolored
stringy EPS (blue). (C) Uninoculated porcine wound. (D) Control. (E) Gauze debrided. (F) Debrisoft debrided. (G) Debrimitt debrided. (H–J) Direct imaging
of postdebridement devices reveal attached clumps of bacteria, with altered morphology [inset, (J)]. Bar (A) = 1lm (A, B), 5 lm (C–G, J; inset), and 20 lm
(H–J). SEM, scanning electron microscopy.
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this time encased in a more globular EPS (pseudoco-
lored blue; Fig. 6B). As with P. aeruginosa, S. aureus
porcine biofilm skin subjected to gauze debridement
retained many S. aureus bacteria with prominent
EPS remaining (Fig. 6E). By contrast, Debrisoft and
Debrimitt debridement appeared to remove the
majority of surface EPS (Fig. 6F, G). Again,S. aureus
bacteria were clearly visible on the monofilament
device fibers following treatment (Fig. 6H, J). Inter-
estingly, S. aureus appeared to be removed in large
EPS encapsulated clumps, particularly evident
following debridement with Debrimitt.
DISCUSSION
Chronic wounds, often refractory to current
treatments, remain a huge challenge in the clinic.3
Bacterial infection has long been implicated in im-
paired wound repair, where some studies suggest
chronicity is prolonged by established bacterial bio-
films comprising pathogens such as P. aeruginosa
and S. aureus.3,20,21 Simple yet efficient removal of
wound biofilms should therefore be particularly
beneficial to promote wound repair. In this study, we
have established an ex vivo single-species porcine
biofilm model using P. aeruginosa and S. aureus.
Using this model, and carefully controlled applica-
tion parameters, we show that new polymer debrid-
ing devices are more effective at removing
established wound biofilms than standard gauze.
Indeed, combination of quantitative and morpholog-
ical assessments revealed that thepolymerdebriding
device Debrimitt was most effective at removing
established biofilms from porcine wound tissue.
While virulence is associated with biofilm prev-
alence, bacterial loads of greater than 105 bacteria
Figure 6. SEM images confirm S. aureus biofilm removal following debridement. (A) Pseudocolored coccoid-shaped S. aureus ( purple). (B) Pseudocolored
globular EPS (blue). (C) Uninoculated porcine wound. (D) Control. (E) Gauze debrided. (F) Debrisoft debrided. (G) Debrimitt debrided. (H–J) Direct imaging
of postdebridement devices reveals attached clumps of bacteria. Bar (A) = 1 lm (A, B), 5lm (C–G), and 20lm (H–J).
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per gram have been linked to nonhealing patho-
physiology.22 Four log10 is also a key measure for
bacterial reduction, being the FDA threshold cri-
teria for dressing/device antibacterial efficacy
claims. Indeed, it has been suggested that a 5 log10
reduction in wound bacteria would require 17
generations to recover, equating to around 12h in a
wound environment.23 Therefore, utilizing mono-
filament debriding products may open a time-
dependent therapeutic window for cotreatment
and biofilm eradication.24 In this study, biofilm
viability plate spread counts indicate that mono-
filament debridement reduced wound biofilm bac-
terial loads by up to 7 log10 (against S. aureus
biofilms), equating to over 16h recovery time
(based on in vitro planktonic culture growth rates).
Amajor strength of this study is the use of ex vivo
porcine skin for biofilm establishment. Tissue
studies have been indicated as more adequate than
in vitromodels for testing the significance of clinical
treatments4 as they provide the opportunity for
bacteria to interact with host tissues (reviewed in
Roberts et al.25). The ex vivo porcine wound model
usedhere provides a close physiological comparison
to human wound tissue26 using clinically relevant
bacteria.21 Indeed, SEM analysis reveals that in
our biofilm model, bacteria are closely integrated
into the porcine tissue, depositingEPS that forman
interface with the host dermal fibers. In vivo mod-
els will provide a further level of relevance, allow-
ing the contribution of host factors such as ischemia
and necrosis on biofilm to be assessed.27 However,
as animal studies are expensive, time consuming,
and technically demanding, we suggest that ex vivo
tissue models allow easier control of experimental
variables and assessment of outcomes.16
Byvirtue of their protectiveEPSmatrix, bacteria
within complex biofilms benefit from increased re-
sistance to treatments and host immunity versus
planktonic species.28 The mechanism of EPS func-
tion has begun to be investigated. For example,
inhibiting synthesis of the EPS component, exopo-
lysaccharide alginate, in P. aeruginosa biofilms
potentiated phagocytosis by activated human leu-
kocytes.29 Further studies inhibiting EPS demon-
strate reduced antibiotic resistance28 or complete
inability to form biofilms (reviewed in Flemming
and Wingender30). Interestingly, virulent biofilm-
forming P. aeruginosa is known to synthesize
exogenous polysaccharides for encapsulation and
annealment to host tissues through carbohydrate-
modulating genes such as algC31. Modulations in
genes coding for motility and aggregation have
been demonstrated in biofilm-forming S. aureus
(reviewed in Jefferson32). Gene expression profil-
ing of planktonic bacteria compared to biofilms has
identified multiple genes which contribute to the
sessile, antibiotic-resistant nature of biofilms.33,34
Despite these studies, identification of bacterial
biofilms in wound tissue remains an area of con-
tention.35 In this study, we used 48h ex vivo estab-
lished biofilms of P. aeruginosa and S. aureus based
on previous published data.4,16 In vitro studies in-
dicate P. aeruginosa biofilm growth within 10h22
and certainly by 24h.36 Similarly, S. aureus, known
to establish more slowly than P. aeruginosa, formed
biofilms in 24h when grown on MH substrate.37
Although the patterns of EPS expression and the
distinct polymers produced differ between species,38
SEM imaging of mature biofilms has previously de-
pictedEPSas long strings (P. aeruginosa30) or cloud-
like clumps (S. aureus,4) surrounding the bacteria
within a biofilm. In this study, we demonstrate the
samemorphological features in our 48h established
ex vivo porcine skin biofilms.
A second important characteristic of established
biofilms is the formation of microcolonies (shown by
SEM37). Maintaining close proximity allows bacte-
ria in biofilm microcolonies to exchange genetic in-
formation and make use of chemical signaling
(quorum sensing19) to increase virulence.39 Our
SEM data reveal that in the ex vivo porcine model,
both P. aeruginosa and S. aureus establish EPS en-
capsulated microcolonies that are characteristic of
established biofilms.4 Interestingly, our data agree
with previous SEM studies suggesting that mono-
filament polymer devices structurally integrate
wound debris.40 In the current study, we observed
clumps of aggregated P. aeruginosa in all three test
groups, while clumped aggregates of S. aureuswere
visible only on the monofilament devices (Fig. 6).
Finally, our inclusion of uninoculated porcine skin
for SEM analysis confirmed that wounded skin had
been adequately cleaned to remove endogenous
bacteria before establishment of species-specific
biofilms. When combined with Gram–Twort, Con A,
Acridine Orange, and FISH staining, to indicate the
regional extent of biofilm presence and removal, our
data indicate (i) established biofilm presence before
debridement and (ii) improved efficacy of monofila-
ment debridement versus standard gauze.
In summary, we describe a 48-h ex vivo porcine
skin biofilm model that exhibits many features of
the established biofilm phenotypes, including EPS
production. Using this model, we demonstrate the
efficacy of monofilament debridement as a clear
alternative to more invasive debridement tech-
niques currently used in the clinic. Quantitative
assessment revealed the monofilament debriding
device, Debrimitt, to provide the greatest reduc-
POLYMER DEBRIDEMENT OF PORCINE WOUND BIOFILMS 483
tion in biofilm bacterial load. Intriguingly, our data
suggest that monofilament devices effectively re-
move both bacteria and EPS and that the me-
chanical debridement process may damage
bacteria in situ, further influencing viability. Our
study highlights further opportunities to carefully
and reproducibly test the efficacy of mechanical
debridement in vivo and in clinical contexts.
INNOVATION
This is we believe, the first study to directly com-
pare the efficacy of monofilament debriding devices
for the removal of established biofilm from skin. We
report standardized conditions for theapplicationand
testing of debriding devices and a portfolio of assess-
ments to quantitatively and qualitatively monitor
biofilm removal. Finally, our data reveal differential
efficacy toward defined bacterial species.
ACKNOWLEDGMENTS AND FUNDING SOURCES
This work was funded by research grants from
the MRC, Innovate UK (Knowledge Transfer
Partnership), and Crawford Healthcare Ltd. The
authors wish to thank Tobias Starborg in the Fa-
culty of Life Sciences, EM Facility for their assis-
tance and the Wellcome Trust for equipment grant
support to the EM Facility.
AUTHOR DISCLOSURE AND GHOSTWRITING
C.S. is an employee of Crawford Healthcare Ltd.
The content of this article was expressly written by
the authors listed. No ghostwriters were used to
write this article.
ABOUT THE AUTHORS
Holly N. Wilkinson, MRes, is studying for a
PhD in the Healing Foundation Centre at The Uni-
versity of Manchester. Andrew J.McBain, PhD, is
a Professor of Microbiology at the University of
Manchester. He leads a research group that focuses
on the interaction ofmicroorganismswith thehuman
body in health and disease, and on clinical and en-
vironmental biofilms.Christian Stephenson, BSc,
has a background in Chemistry with extensive ex-
perience inmedical devices product development and
wound management.Matthew J. Hardman, PhD,
formerly the Edmond de Rothschild Senior Fellow in
Ageing Research, is currently a senior lecturer in the
Healing Foundation Centre at The University of
Manchester. He received his PhD in Skin Develop-
mental Biology under the supervision of Professor
Carolyn Byrne at TheUniversity ofManchester. The
primary focus of his research is elucidatingmolecular
and cellular correlates topathologicalwoundhealing.
KEY FINDINGS
 Monofilament debridement efficiently removes estab-
lished bacterial biofilms ex vivo.
 S. aureus and P. aeruginosa biofilms are differentially
susceptible to debridement.
 Debridement removes both EPS and wound bacteria.
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Abbreviations and Acronyms
ANOVA ¼ analysis of variance
CFU ¼ colony forming units
ConA ¼ concanavalin A
DAPI ¼ 4¢,6-diamidino-2-phenylindole
EPS ¼ extracellular polymeric substances
FISH ¼ fluorescent in situ hybridization
MH ¼ Mueller Hinton
O/N ¼ overnight
OCT ¼ optimum cutting temperature
PBS ¼ phosphate-buffered saline
SEM ¼ scanning electron microscopy
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